We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Chugai and Debiopharm Announce an Exclusive License Agreement for FF284
News

Chugai and Debiopharm Announce an Exclusive License Agreement for FF284

Chugai and Debiopharm Announce an Exclusive License Agreement for FF284
News

Chugai and Debiopharm Announce an Exclusive License Agreement for FF284

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Chugai and Debiopharm Announce an Exclusive License Agreement for FF284"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Chugai Pharmaceutical Co., Ltd. and Debiopharm Group™ have announced that on December 17, 2012, they entered into a licensing agreement regarding FF284 (called Debio 1347 by Debiopharm) discovered by Chugai and which is about to start clinical development in oncology.

Under this license agreement, Chugai will grant Debiopharm an exclusive license to develop and commercialize FF284 (Debio 1347) in all countries worldwide including Japan.

Under the same agreement, Chugai will grant a non-exclusive license to develop and commercialize a companion diagnostic for FF284 (Debio 1347).

According to the terms of the license, Debiopharm and Chugai will collaborate to conduct a Phase I dose escalation study. In return for the license, Chugai will receive an upfront fee, milestone and royalty payments from Debiopharm.

“We are delighted that we have concluded a license agreement for the development and marketing of FF284 with Debiopharm” said Tatsuro Kosaka, President and COO of Chugai. “We will continue to cooperate with Debiopharm in order to deliver FF284 to cancer patients as soon as possible.”

“We are happy to combine forces with Chugai for the development of Debio 1347,” said Rolland-Yves Mauvernay, President and founder of Debiopharm Group™.

Mauvernay continued, “Due to its profile, Debio 1347 is expected to become a tailored treatment with high anti-tumour activity, which is very promising.”

Advertisement